Donna Melancon Email & Phone Number

Baton Rouge, Louisiana

Humlebæk, Denmark, Dk

Humlebæk, Denmark, Dk

Minneapolis, Mn, Us

I was assigned to an underperforming territory with declining sales due to territory vacancy for 8 months and have been successful in driving sales growth for InterStim therapy (implantable sacral nerve neuro-stimulation device used for bladder and bowel control) by calling on and building relationships with surgeons in urology, OB/GYN, and colorectal specialties in the Baton Rouge territory. • Brought on a total of four new implanting surgeons (three urologists and one OB/GYN) in an extremely competitive and specialized market with extensive rural areas and complex reimbursement issues.• Generated an immediate impact with $1.6 million in first year sales for Baton Rouge territory with a 43% increase in Q3 & Q4 Fiscal 2016 (first two quarters in the territory) versus Q1 & Q2 2016 revenue. • Implemented systematic processes for physicians to track and manage patients undergoing InterStim evaluations that resulted in an 85% conversion rate.• Spearheaded discussions with CFOs and administrators to overcome reimbursement challenges and threats of implant program termination by educating key decision-makers on benefits of the InterStim therapy. • Implemented patient management worksheets that built physician confidence and advocacy by providing implanting surgeons with updates on patients’ progress.• Educated patients on overactive bladder care, procedures, trial expectations, and device operation; directly involved in patient’s care pre, intra, and post-operatively.

I won awards and earned top rankings for sales of the women’s surgical implant portfolio including slings and prolapse repair systems to urologists, urogynecologists, and surgical gynecologists in a territory covering South Louisiana and South Mississippi. Drove implant sales by using a clinical sales approach, providing support in the OR during procedures, providing training on implant technique (cadaver labs and in-services), and increasing product accessibility in major hospital accounts.• Ranked Top 15 of 70 reps in the US for 2013, 2010, and 2008.• Ranked #1 in Continence Sales for 2010 for the Southeast area. • Finished 2008 ranked #6 in the US for 2008 at 126% of sales plan.• Turned around an underperforming territory (ranked bottom 33% of the US) with declining sales trend and strong competitor foothold from Boston Scientific and Johnson & Johnson.• Implemented aggressive sales efforts generating 100% revenue growth in 1st 18 months (05/2007-12/2008).• Increased ranking from bottom 33% in the US and achieved Top 10 territory ranking from 2007 to 2008.• Ranked #1 in Prolapse Sales in the Southwest area in 2008.• Selected to the National Clinical Review Incontinence Triage Team (2015), as a Regional MiniArc Campaign Leader (2014), National Sales Advisory Council Member (2011), and as a Sales Trainer/Group Facilitator at national, area, and regional sales meetings (2010-2015).

Marlborough, Ma, Us

I exceeded performance expectations for sales growth of cardiac device therapy and built physician referral sources that substantially increased patients for device therapy through extensive marketing and CME accredited programs targeting cardiologists and internists. Results were achieved by strategically analyzing monthly/quarterly implant data to identify and continue targeting high-referring physicians. • Ranked #1 as Top Account Manager in the Southeast area Q1 2005. • Exceeded sales plan for 2003 and 2005. • Recognized as one of only four Account Managers (out of 80) to exceed 2005 sales plan. • Appointed as a member of the Guidant National Marketing Advisory Panel.

I turned around an underperforming market selling urological and neurological products (Detrol LA, Celebrex, Mirapex, and Bextra) to high-volume urologists and neurologists in a large territory covering South Louisiana to Hattiesburg, MS. • Increased territory ranking from #59 of 61 to #16 in less than 10 months. • Ranked as #1 top market share growth performer in Southwest region for the entire portfolio in 2002. • Finished 140% to plan for COX-2 portfolio and 110% to plan for Detrol LA product line in 2002. • Increased territory market 10 share points (28% growth) for Detrol LA in 10 months.

Lawrence Township, Nj, Us

I contributed to the successful launch and sales growth of Plavix (new antiplatelet therapy) by calling on large cardiology practices and hospital accounts in the North Atlanta market. I developed key cardiologists as thought leaders by targeting to the region’s largest cardiology practices. • Won 2000 District Leadership Award for overall contributions to the success of the district. • Won 1999 Excellence Award for outstanding sales achievement. • Generated the highest Glucophage market share (41%) in the Southeast area during 1998.